A Novel Pharmacophore Model to Identify Leads for Simultaneous Inhibition of Anti-coagulation and Anti-inflammatory Activities of Snake Venom Phospholipase A2

Abdul Wadood1,3, Syed Abid Ali2, Rabia Sattar1, Muhammad Arif Lodhi2 and Zaheer Ul-Haq1,*  

1Dr Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan  
2HEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan  
3Department of Biochemistry, Shankar Campus, Abdul Wali Khan University, Mardan, Pakistan  
*Corresponding author: Zaheer Ul-Haq, zaheer.qasmi@iccs.edu

In addition to catalytic action, snake venom phospholipase A2 induces several pharmacological effects including neurotoxicity, cardiotoxicity as well as anti-coagulant and anti-platelet aggregation effects. Therefore, strategy to identify dual inhibitor for this enzyme will be of much importance in medical research. In this paper, structure-based pharmacophore mapping, molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions were employed in a virtual screening strategy to identify new hits for dual inhibition of anti-coagulation and inflammation of phospholipase A2. A structure-based pharmacophore map was modeled which comprised of important interactions as observed in co-crystal of phospholipase A2 and its dual inhibitor indomethacin. The generated model was used to retrieve molecules from ChemBridge, a free database of commercially available compounds. A total of 381 molecules mapped on the developed pharmacophore model from ChemBridge database. The hits retrieved were further screened by molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions using Genetic Optimization for Ligand Docking and MOE.

Based on these results, 32 chemo-types molecules were predicted as potential lead scaffolds for developing novel, potent and structurally diverse dual inhibitor of phospholipase A2.

Key words: docking, dual inhibitor, pharmacophore, phospholipase A2, snake, venom, virtual screening

Phospholipase A2 (PLA2) is an important family of different enzymes that exhibits diverse substrate specificities, subcellular localization, requirements of cofactor, and cellular function (1). The PLA2 class of enzymes especially catalyzes the hydrolysis of the 2-acyl ester bond of phospholipids to yield arachidonic acid that is used as a substrate by cyclooxygenase (COX) and lipooxygenase enzymes, as a result eicosanoids is formed (2,3). Snake venom PLA2, in addition to catalytic action, also mediates several pharmacological disorders, for example, myotoxicity, neurotoxicity, cardiotoxicity as well as anti-coagulant, edema inducing, hemolytic and platelets modulating effects (4). The primary consideration is that the catalytic properties and pharmacological actions were related, and all the activities were based on the specific and critical phospholipids hydrolysis (5).

Alternatively, it has been reported that the pharmacological properties of snake venom PLA2 are not necessarily dependent on their catalytic activity, and it might be due to the protein–protein interactions involving a specific site on the surface of protein (6,7). So far, these pharmacological sites are neither clearly defined nor their binding modes are established. Consequently, the effective chemical entities have not been designed to prevent the interactions of these sites to overcome the harmful pharmacological effects, whereas the substrate binding region and the residues involved in the catalytic activities of PLA2 enzymes are well established. A number of three-dimensional (3D) structures of different PLA2 isoforms from a variety of sources have been recently resolved (8–18). To understand the mechanism of catalytic actions of PLA2, a number of inhibitors have been designed for the inhibition of their enzymatic activity. Several complex structures of PLA2 with natural compounds, synthetically designed inhibitors as well as substrate analogues, have also been published (9,19–26). It has also been reported that the anti-inflammatory activity showed by non-steroidal anti-inflammatory drugs has been attributed to their binding to PLA2 and COX enzymes (27–33).

The anti-coagulant activity in snake venom PLA2 was also reported many years ago by Buffa et al. (34,35). It has been reported that the anti-coagulant activity in various snake venom PLA2 is greatly varied. Based on their activities, the PLA2 was further classified into strong, weak, and non-coagulant compounds (4,36). It has also been suggested that the anti-coagulant site exists between residues 54–77. Although the exact nature of the structure of this...
anti-coagulant loop is not clearly understood so far, it has been shown that the strong anti-coagulant activity of PLA₂ attributed to the presence of basic residues at precise positions in the segment 54–77. For example, isoform of PLA₂ from Daboia russelli pulchella possesses five basic residues in the loop 54–77 demonstrating its potential to be powerful anti-coagulant. However, the ligand-binding mode for inhibiting the anti-coagulant activity of PLA₂ is not fully understood, and hence, the ligand could not be designed to inhibit the anti-coagulant action of PLA₂. Indomethacin has been reported long time ago as a non-selective COX-2 inhibitor (37). In recent studies, it has also been reported that indomethacin inhibits group II PLA₂, but its unusual kinetic properties could not be explained (38,39). These studies demonstrate that the binding mode of indomethacin is very different as compare to other molecules that bind to the substrate binding site of PLA₂ enzyme. It was also indicated that indomethacin blocks the anti-thrombotic action of PLA₂, thus suggesting that indomethacin might also be involved in inhibiting its anti-coagulant binding site (40). Very recently, the co-crystallized structure of PLA₂ with indomethacin has been resolved, to understand its binding mode with PLA₂ and the mechanisms of its actions against both catalytic and anti-coagulant actions. A remarkable new ligand-binding site has been identified, which demonstrates that indomethacin binds to the amino acid residues that are significant for the catalytic action of the enzyme as well as for its anti-coagulant activity.

In recent years, high-throughput virtual screening has been emerging as a complementary to high-throughput screening in an attempt to discover novel potential lead compounds in the process of drug discovery (41). Thus, to identify new and potent compounds that inhibit both the catalytic and anti-coagulant activities of snake venom PLA₂ like indomethacin, structure-based pharmacophore modeling and virtual screening may consider as an effective approach. This paper describes the structure-based pharmacophore modeling to identify the pharmacophoric features required for simultaneous inhibition of anti-coagulant and inflammatory effects by virtual screening, molecular docking, protein–ligand interaction fingerprints (PLIFs), binding energy calculations, and binding affinity predictions.

Materials and Methods

**Generation of structure-based pharmacophore model**

In the present study, the only crystal structure of PLA₂ in complex with a dual inhibitor indomethacin (3H1X.pdb) was used as starting structure for the generation of structure-based pharmacophore models (42). LIGANDSCOUT (LS) is a tool that allows the automatic construction and visualization of 3D pharmacophore from structural data of macromolecules/ligand complexes (43). For the LS algorithm, chemical features include hydrogen bond donors and acceptors as directed vectors, and positive and negative ionizable regions as well as lipophilic areas are represented by spheres. Moreover, to increase the selectivity, the LS model includes spatial information regarding areas inaccessible to any potential ligand, thus reflecting possible steric restrictions. In particular, excluded volume spheres placed in positions that are sterically forbidden are automatically added to the generated pharmacophore model. The software LS was applied to the detection and interpretation of crucial interaction patterns between PLA₂ and ligand. LS extracts and interprets ligands and their macromolecular environment from PDB files and automatically generates and visualizes advanced 3D pharmacophore models.

LIGANDSCOUT may also be used to construct pharmacophore of varying degrees of sophistication, suitable for export to different programs. In the present study, MOE-compatible 3D-pharmacophore model was first developed by LS using default parameters, and then, it was exported and converted into a Molecular Operating Environment, pharmacophore query for virtual screening (http://www.chemcomp.com). Prior to screening, it was necessary to make a number of adjustments, because feature interpretation differs slightly between the two programs. Those aromatic rings that LS classified simply as hydrophobic groups were classified as either aromatic or hydrophobic in MOE, using the PPCH_All scheme (which incorporates directionality of hydrogen bond donors and acceptors, and orientation of aromatic rings). As in LS pharmacophore, the aromatic ring is not directly classified as such (because of lack of detection of \( \pi-\pi \) stacking or cation--\( \pi \) interactions) but rather as a set of hydrophobic atoms, can be interpreted in MOE in a manner that is useful in the prediction of right compounds in virtual screening.

**Pharmacophore-based virtual screening**

The ChemBridge database (http://www.chembridge.com), which allows the user to download compounds structures from a variety of vendors as SDF files, was used in this preliminary screen. Using MOE, the database was washed, and the 3D structure of each compound was built using the MMFF94x force field. Then for each compound, the low-energy conformers were generated using Conformal Import methodology implemented in MOE software. After assessing the pharmacophore query, virtual screening was carried out using the software MOE against ChemBridge database. Because some changes may occur when the pharmacophore is exported from LS to MOE environment, therefore, the pharmacophore queries were validated before using it for virtual screening. To reduce the data of identified hits, they were docked into the recently identified binding pocket of PLA₂, and the PLIFs were developed using MOE. Binding energies and binding affinities were calculated using LIG (Chemical Computing Group, Montreal, Quebec, Canada) implemented in MOE to prioritize the final hits.

**Molecular docking**

Molecular docking studies were performed using Genetic Optimization for Ligand Docking (GOLD) from Cambridge Crystallographic Data Center, UK (44). GOLD uses genetic algorithm for docking flexible small molecules (ligands) into binding site of macromolecules (target proteins) to investigate the full range conformational flexibility of ligand with partial flexibility of the receptor. The ligand-binding energy with receptor was predicted via GOLD score implemented in GOLD. The total GOLD score, which is represented as ‘Fitness’, was calculated from the contribution of hydrogen bonds and van der Waals interactions between receptor and ligand as well as the contribution of intra-molecular hydrogen bonds and intra-molecular strain in the
ligand. Receptor co-ordinates of the crystal structure of PLA$_2$-inhibitor complex were used to define the binding site for molecular docking studies. All the solvent molecules except involved in ligand binding (i.e. W158, W261, and W284) in the crystal structure were removed, and hydrogen atoms were added to the whole protein. The ligand-binding site for docking was defined as a collection of amino acids enclosed within a sphere of 10 Å radius around the co-ordinates of indomethacin, which is the inhibitor molecule present in the binding site of PLA$_2$-inhibitor complex. Top 10 docked poses were allowed to be saved with the early termination option of quitting the genetic optimization calculation for a ligand if the RMSD between any five conformations of the particular ligand is <1.5 Å. All other parameters were kept at their default values. Molecular interactions were observed using PLIF and LIGX software implemented in MOE.

**Computation of generalized Born interaction energies and binding affinity**

To predict the most promising compounds, binding affinities of the hits-PLA$_2$ complexes were calculated with generalized Born/volume integral (GB/VI) implicit solvent method using LIGX tool in MOE (45). Generalized Born interaction energy is the non-bonded interaction energy between the macromolecule and the ligand, which comprises van der Waals, Coulomb electrostatic interaction, and implicit solvent interaction energies; however, ligand and receptor macromolecule strain energies are not taken into account. LIGX is the name for a collection of procedures and capabilities in MOE for conducting interactive ligand modification and energy minimization in the binding pocket of a flexible receptor. In LIGX calculations, the receptor atoms far from the ligand are held fixed (constrained not to move) while receptor atoms in the vicinity of the ligand (in the active site) are allowed to move but are subject to tether restraints that discourage gross movement. The ligand atoms can be configured as either free to be move or subject to similar tethers as the receptor. Prior to calculation of binding energy, binding pocket of PLA2 and the ligand in the complex were subjected to energy minimization. During the minimization, the positions of residues of PLA2 that are located 10 Å away from ligand were constrained. The calculated binding affinities of each compound are reported in the units of pKi.

**Results and Discussion**

**Generation of structure-based pharmacophore model**

As shown in Figures 1 and 2, the pharmacophore model automatically generated by the LS program includes four features: three hydrogen bond acceptors (HBA) and one hydrophobic group. Besides, the program automatically generated several excluded volumes in the model. The HBA features points toward the carboxylic and methoxy oxygen atoms of the ligand from the Lys$^{69}$ and water molecules W158, 261, 284, and 358, respectively. The hydrophobic groups are located on the methyl group adjacent to the indole ring of the ligand. The developed pharmacophore model was exported into MOE. Prior to screening, it was necessary to make a number of adjustments, as feature interpretation varies slightly between the two programs. As in LS pharmacophore, the aromatic ring of the compound in the complex was not classified as aromatic or hydrophobic features; thus, these were interpreted in MOE, using the PPCH$_{All}$ scheme. Two modifications were made on this model to obtain appropriate model for virtual screening. The first modification is about the chlorobenzyl ring. It is clear that it is an aromatic group, but the LS could not interpret this ring as an aromatic group automatically. In MOE, additional features were developed using the MOE pharmacophore query editor. First, an aromatic feature was developed on the chlorobenzyl ring, and a hydrophobic feature was developed on the phenyl ring of indole moiety of the ligand. This modified pharmacophore model was then validated by screening the test database. In the test database, we kept the compound (i.e. indomethacin) present in complex structure. First, the indomethacin was extracted, and then, hydrogen atoms were added and energy minimized by using MOE. The minimized structure of indomethacin was added to the test database. After screening, the test compound was correctly mapped by the modified pharmacophore model as shown in Figure 2A. The result verified the validity of our modified pharmacophore model that can be used for the screening of large databases.

**Pharmacophore-based virtual screening**

The modified validated pharmacophore model was then used as an in silico filter to screen the ChemBridge database (http://www.chembridge.com) of commercially available compounds. The ChemBridge database compounds in SDF format were loaded into MOE environment where the 3D structure of each compound was modeled using MMFF94x force field. The Conformation Import methodology was applied to generate low-energy conformations for each compound. All these compounds and their respective conformations were saved in MOE database. The conformers of each compound were then filtered by the pharmacophore model. To be considered as hit, the compound has to fit all the features of the pharmacophore. From the pharmacophore-based virtual screening, 381 hits were identified that mapped on the developed pharmacophore model (i.e. having the specified requirements). These initially identified hits were selected for further evaluation using docking studies.
Table 1: GOLD fitness scores, binding energies, and binding affinities of most promising lead compounds. See Materials and Methods for details.

<table>
<thead>
<tr>
<th>S. no.</th>
<th>Compound structure</th>
<th>GOLD score</th>
<th>Binding energy (MM/GBVI kcal/mol)</th>
<th>Binding affinity (pKi)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><img src="image1" alt="Compound 1" /></td>
<td>53.79</td>
<td>-16.98</td>
<td>8.41</td>
</tr>
<tr>
<td>2</td>
<td><img src="image2" alt="Compound 2" /></td>
<td>63.24</td>
<td>-18.27</td>
<td>7.43</td>
</tr>
<tr>
<td>3</td>
<td><img src="image3" alt="Compound 3" /></td>
<td>53.69</td>
<td>-17.35</td>
<td>7.84</td>
</tr>
<tr>
<td>4</td>
<td><img src="image4" alt="Compound 4" /></td>
<td>47.37</td>
<td>-13.82</td>
<td>8.25</td>
</tr>
<tr>
<td>5</td>
<td><img src="image5" alt="Compound 5" /></td>
<td>57.97</td>
<td>-16.77</td>
<td>7.12</td>
</tr>
<tr>
<td>6</td>
<td><img src="image6" alt="Compound 6" /></td>
<td>48.62</td>
<td>-14.65</td>
<td>5.66</td>
</tr>
<tr>
<td>7</td>
<td><img src="image7" alt="Compound 7" /></td>
<td>48.24</td>
<td>-21.31</td>
<td>7.23</td>
</tr>
<tr>
<td>8</td>
<td><img src="image8" alt="Compound 8" /></td>
<td>59.56</td>
<td>-19.68</td>
<td>7.35</td>
</tr>
<tr>
<td>9</td>
<td><img src="image9" alt="Compound 9" /></td>
<td>55.24</td>
<td>-17.47</td>
<td>6.62</td>
</tr>
</tbody>
</table>
### Table 1: (Continued)

<table>
<thead>
<tr>
<th>S. no.</th>
<th>Compound structure</th>
<th>Gold score</th>
<th>Binding energy (MM/GBVI kcal/mol)</th>
<th>Binding affinity (pKi)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td><img src="image1" alt="Compound 10" /></td>
<td>59.82</td>
<td>-19.46</td>
<td>7.40</td>
</tr>
<tr>
<td>11</td>
<td><img src="image2" alt="Compound 11" /></td>
<td>66.57</td>
<td>-17.69</td>
<td>9.47</td>
</tr>
<tr>
<td>12</td>
<td><img src="image3" alt="Compound 12" /></td>
<td>47.54</td>
<td>-14.35</td>
<td>8.22</td>
</tr>
<tr>
<td>13</td>
<td><img src="image4" alt="Compound 13" /></td>
<td>46.77</td>
<td>-16.45</td>
<td>6.49</td>
</tr>
<tr>
<td>14</td>
<td><img src="image5" alt="Compound 14" /></td>
<td>67.76</td>
<td>-22.50</td>
<td>9.12</td>
</tr>
<tr>
<td>15</td>
<td><img src="image6" alt="Compound 15" /></td>
<td>50.60</td>
<td>-21.31</td>
<td>7.60</td>
</tr>
<tr>
<td>16</td>
<td><img src="image7" alt="Compound 16" /></td>
<td>63.90</td>
<td>-23.21</td>
<td>6.76</td>
</tr>
<tr>
<td>17</td>
<td><img src="image8" alt="Compound 17" /></td>
<td>58.16</td>
<td>-21.38</td>
<td>7.71</td>
</tr>
<tr>
<td>18</td>
<td><img src="image9" alt="Compound 18" /></td>
<td>48.16</td>
<td>-21.10</td>
<td>7.07</td>
</tr>
<tr>
<td>19</td>
<td><img src="image10" alt="Compound 19" /></td>
<td>52.53</td>
<td>-24.66</td>
<td>8.46</td>
</tr>
<tr>
<td>S. no.</td>
<td>Compound structure</td>
<td>Gold score</td>
<td>Binding energy (MM/GBVI kcal/mol)</td>
<td>Binding affinity (pKi)</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------</td>
<td>------------</td>
<td>----------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>20</td>
<td><img src="image" alt="Structure 20" /></td>
<td>59.18</td>
<td>−17.48</td>
<td>8.18</td>
</tr>
<tr>
<td>21</td>
<td><img src="image" alt="Structure 21" /></td>
<td>55.22</td>
<td>−16.20</td>
<td>8.16</td>
</tr>
<tr>
<td>22</td>
<td><img src="image" alt="Structure 22" /></td>
<td>47.22</td>
<td>−13.90</td>
<td>6.58</td>
</tr>
<tr>
<td>23</td>
<td><img src="image" alt="Structure 23" /></td>
<td>60.46</td>
<td>−20.41</td>
<td>8.49</td>
</tr>
<tr>
<td>24</td>
<td><img src="image" alt="Structure 24" /></td>
<td>49.78</td>
<td>−13.88</td>
<td>7.23</td>
</tr>
<tr>
<td>25</td>
<td><img src="image" alt="Structure 25" /></td>
<td>52.78</td>
<td>−15.53</td>
<td>7.93</td>
</tr>
<tr>
<td>26</td>
<td><img src="image" alt="Structure 26" /></td>
<td>51.20</td>
<td>−18.91</td>
<td>6.39</td>
</tr>
<tr>
<td>27</td>
<td><img src="image" alt="Structure 27" /></td>
<td>65.73</td>
<td>−17.79</td>
<td>9.15</td>
</tr>
<tr>
<td>28</td>
<td><img src="image" alt="Structure 28" /></td>
<td>53.54</td>
<td>−17.78</td>
<td>8.30</td>
</tr>
<tr>
<td>29</td>
<td><img src="image" alt="Structure 29" /></td>
<td>58.25</td>
<td>−20.39</td>
<td>8.59</td>
</tr>
</tbody>
</table>
Molecular docking

To deduce the promising compounds for dual inhibitors of PLA₂, all the initial hits were docked into the recently identified binding pocket of PLA₂ using the automated GOLD docking program. Prior to dock the initial hits, the ligand (i.e. indomethacin) from the complex structure was extracted and re-docked into the binding pocket to validate the docking protocol. The docked conformation corresponding to the high GOLD fitness score was selected as the most promising binding conformation. The root mean square deviation (RMSD) between the docked and experimentally determined conformation was calculated.

Table 1: (Continued)

<table>
<thead>
<tr>
<th>S. no.</th>
<th>Compound structure</th>
<th>GOLD score</th>
<th>Binding energy (MM/GBVI kcal/mol)</th>
<th>Binding affinity (pKi)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td><img src="image" alt="Compound structure" /></td>
<td>52.22</td>
<td>−20.51</td>
<td>7.37</td>
</tr>
<tr>
<td>31</td>
<td><img src="image" alt="Compound structure" /></td>
<td>55.99</td>
<td>−13.38</td>
<td>7.25</td>
</tr>
<tr>
<td>32</td>
<td><img src="image" alt="Compound structure" /></td>
<td>57.92</td>
<td>−25.17</td>
<td>7.15</td>
</tr>
<tr>
<td>Indomethacin</td>
<td><img src="image" alt="Compound structure" /></td>
<td>58.00</td>
<td>−13.28</td>
<td>6.98</td>
</tr>
</tbody>
</table>

Figure 2: (A) Three-dimensional pharmacophore model generated by LIGANDSCOUT from the complex structure of phospholipase A₂ and indomethacin. The red arrows indicate the hydrogen bond acceptor features, the yellow sphere indicates the hydrophobic feature in the ligand, whereas the gray spheres represent the restricted volume in the receptor. (B) The fitting of indomethacin on modified three-dimensional pharmacophore model developed by using MOE pharmacophore query editor. The pink, green, and yellow color spheres indicated hydrogen bond acceptor, aromatic and hydrophobic features, respectively, whereas the gray color spheres represented the excluded volumes.

Molecular docking

To deduce the promising compounds for dual inhibitors of PLA₂, all the initial hits were docked into the recently identified binding pocket of PLA₂ using the automated GOLD docking program. Prior to dock the initial hits, the ligand (i.e. indomethacin) from the complex structure was extracted and re-docked into the binding pocket to validate the docking protocol. The docked conformation corresponding to the high GOLD fitness score was selected as the most promising binding conformation. The root mean square deviation (RMSD) between the docked and experimentally determined conformation was calculated.
using SVL script of MOE and found to be equal to 1.33 Å, suggesting that a high docking reliability of GOLD in reproducing the experimentally determined binding mode for PLA2. The GOLD docking software and the parameters set could be extended to search the PLA2 binding conformations for other compounds accordingly. Using the same docking protocol, all the initial hits were docked into the binding pocket of PLA2. Furthermore, on the basis of GOLD fitness score, the top-ranked 100 compounds were selected for further detail investigations. For the top-ranked pose of all the selected compounds, PLIFs were generated by MOE, and those compounds that revealed significant interactions with important residues of recently identified binding pocket (i.e. Asp49, His48, Lys69) and water molecules in the catalytic and anti-coagulant active site regions of PLA2 were picked as promising hits. Protein–ligand interaction fingerprints implemented on MOE classify the interactions between a ligand and the residues on the binding site into various types of weak and strong interactions. Among the top-ranked 100 compounds, 53 compounds showed the crucial interaction with the enzyme via PLIFs.

**Computation of binding affinity and expert visual inspection**

Finally, binding energy and binding affinity for all the 53 compounds including indomethacin were calculated using LIGX implemented in MOE to prioritize identified promising hits. The criteria for the selection of the most promising hits were compounds having binding energy and binding affinity equal to or good as compare to the binding energy and binding affinity calculated for indomethacin, visualization of each compound in the binding pocket and the selection of only those compounds exhibiting interactions with both catalytic and anti-coagulant region of PLA2, and diversity of the compounds. Applying the above-mentioned criteria, 32 compounds of 53 fulfill the specific requirements summarized in Table 1. The pharmacophore mapping, PLIFs, binding mode, binding energy, and binding affinity prediction showed that these predicted lead hits might act as good lead compounds for the development of novel, potent, and structurally diverse dual inhibitors of snake venom PLA2 enzyme.

**Figure 3:** Two-dimensional representations of the interactions of (A) indomethacin, (B) compounds 14, (C) compound 27, and (D) compound 29 and snake venom phospholipase A2. Hydrogen bonds are represented with green dashed lines.
Binding interactions of finally selected compounds

The docking studies revealed that almost all finally selected lead hits showed similar binding interactions as that of indomethacin to both catalytic and anti-coagulant regions of PLA2 enzyme. For example, compound 14 for which the strong binding affinity (0.91 pKi), lower binding energy (−22.5), and high Gold fitness score (67.76) were observed showed the binding interaction similar to that of indomethacin (Table 1). From the docked conformation, it was also predicted that the oxygen atom of hydroxy group attached to the pyrrolidine ring and nitrogen atom in pyridine ring of the compound 14 established interaction with the amino acid residues Asp69, Gly30, His10, and Lys69 in a similar manner of indomethacin to the same residues (Figure 3A,B). Similarly, it was also predicted that the oxygen atoms attached to the sulfur atom in compound 27 interact in the same fashion to the important residues of the enzyme (Figure 3C). Likewise, in the binding mode of compound 29, oxygen atom of methoxy group attached to the phenyl ring of the compound interacts with the catalytic region, whereas the carbonyl oxygen interacts with anti-coagulant region of PLA2 in a similar fashion as indomethacin (Figure 3D). From the docking poses of the selected compounds, it was observed that there are some specific functional groups that interact with the catalytic and anti-coagulation regions and fit well in the newly identified binding pocket of snake venom PLA2 enzyme.

Conclusion

The aim of this study was to generate a pharmacophore model to identify structurally diverse lead hits. The identified hits might be used for developing novel and potent inhibitors for simultaneous inhibition of anti-coagulant and inflammatory affects of snake venom enzyme PLA2. A structure-based pharmacophore was developed based on the complex structure of PLA2 and indomethacin. The developed pharmacophore model was used for the screening of ChemBridge database. The identified hits were further evaluated by molecular docking, PLIFs development, binding energy calculation, and binding affinity prediction. As a result, 32 lead hits were reported that fulfilled all the criteria for the design of compounds that might act as good leads for development of novel, potent, and structurally diverse compounds for dual inhibition. From the binding mode, predicted by docking, it was observed that there are some specific groups that mimic the binding mode of indomethacin and fit well to both of the catalytic and anti-coagulation region of PLA2 enzyme. Further studies toward the synthesis and structure–activity relationship of the above-mentioned lead compounds with different snake venom PLA2 are in progress and will be reported elsewhere.

Acknowledgments

Financial support from ASEA-UNINET under the Austrian-Pakistan Cooperation Project in Computational Chemistry (APCPC) is highly acknowledged. We are extremely grateful to Dr Reaz uddin (Dr Panjwani Center for Molecular Medicine and Drug Research, University of Karachi, Pakistan) for his useful suggestions and meaningful discussions.

References


440


Note